| Bioactivity | TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC50s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively[1]. | ||||||||||||
| Invitro | TC-S 7005 markedly induces myofibroblast differentiation and reduces fibroblast proliferation rates[2]. Cell Proliferation Assay[2] Cell Line: | ||||||||||||
| Name | TC-S 7005 | ||||||||||||
| CAS | 1082739-92-1 | ||||||||||||
| Formula | C21H17N3O3 | ||||||||||||
| Molar Mass | 359.38 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hanan EJ, et al. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5186-9. [2]. Stephan Reinhard Künzel, et al. Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation. bioRxiv 445098 |
TC-S 7005
CAS: 1082739-92-1 F: C21H17N3O3 W: 359.38
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC50s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respect
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.